FY2027 EPS Estimate for Telix Pharmaceuticals Cut by Analyst

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Analysts at William Blair cut their FY2027 EPS estimates for Telix Pharmaceuticals in a note issued to investors on Thursday, August 21st. William Blair analyst A. Hsieh now anticipates that the company will post earnings per share of $0.49 for the year, down from their previous forecast of $0.58. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share.

Several other research analysts also recently weighed in on TLX. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. HC Wainwright started coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They issued a “buy” rating and a $23.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $22.33.

Telix Pharmaceuticals Stock Up 3.2%

Telix Pharmaceuticals stock opened at $12.48 on Monday. The firm’s 50 day simple moving average is $14.47 and its 200-day simple moving average is $16.25. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66. Telix Pharmaceuticals has a fifty-two week low of $10.50 and a fifty-two week high of $30.36.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Private Advisor Group LLC acquired a new stake in shares of Telix Pharmaceuticals during the first quarter worth approximately $170,000. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $297,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals during the first quarter worth approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.